Moleculin Biotech, Inc. (MBRX): Price and Financial Metrics
GET POWR RATINGS... FREE!
MBRX Stock Price Chart Interactive Chart >
MBRX Price/Volume Stats
| Current price | $1.51 | 52-week high | $3.99 |
| Prev. close | $1.44 | 52-week low | $1.02 |
| Day low | $1.41 | Volume | 67,200 |
| Day high | $1.55 | Avg. volume | 114,942 |
| 50-day MA | $1.62 | Dividend yield | N/A |
| 200-day MA | $2.06 | Market Cap | 43.15M |
Moleculin Biotech, Inc. (MBRX) Company Bio
Moleculin Biotech, Inc., a preclinical and clinical-stage pharmaceutical company, focuses on the development of anti-cancer drug candidates. Its lead drug candidate is liposomal Annamycin, an anthracycline intended for the treatment of relapsed or refractory acute myeloid leukemia. The company was founded in 2015 and is based in Houston, Texas.
Latest MBRX News From Around the Web
Below are the latest news stories about Moleculin Biotech Inc that investors may wish to consider to help them evaluate MBRX as an investment opportunity.
Moleculin Biotech Annamycin Doublet Therapy Shows 68% Overall Survival In Animal StudyMoleculin Biotech Inc (NASDAQ: MBRX ) has announced preliminary results supporting the successful conclusion of its second Phase 1 trial in Poland, evaluating Annamycin for relapsed and refractory acute myeloid leukemia (AML). Moleculin determined a dose of 240 mg/m2 as the Recommended Phase 2 Dose (RP2D), subject to final approval of the Safety Review Full story available on Benzinga.com |
Moleculin Provides Annamycin AML Program Update and Outlines Next Steps to Advance Towards Late-Stage DevelopmentMoleculin Biotech, Inc., (Nasdaq: MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting highly resistant tumors and viruses, today announced preliminary results supporting the successful conclusion of its second Phase 1 trial (MB-105) in Poland evaluating Annamycin for the treatment of relapsed and refractory acute myeloid leukemia (AML), where Moleculin determined a dose of 240 mg/m2 as the Recommended Phase 2 Dose (RP2 |
Moleculin Biotech (MBRX) Receives a Buy from Maxim GroupMaxim Group analyst Jason McCarthy maintained a Buy rating on Moleculin Biotech (MBRX – Research Report) on February 2 and set a price target of $5.00. The company's shares closed last Friday at $1.49, close to its 52-week low of $1.31. According to TipRanks.com, McCarthy has currently 0 stars on a ranking scale of 0-5 stars, with an average return of -22.9% and a 14.7% success rate. McCarthy covers the Healthcare sector, focusing on stocks such as Appili Therapeutics Inc Class A, Reviva Pharmaceuticals Holdings, and Brainstorm Cell Therapeutics. The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Moleculin Biotech. |
Companies Like Moleculin Biotech (NASDAQ:MBRX) Are In A Position To Invest In GrowthWe can readily understand why investors are attracted to unprofitable companies. For example, although... |
Moleculin Biotech, Inc. to Present at the Virtual Investor 2022 Top Picks ConferenceMoleculin Biotech, Inc., (Nasdaq: MBRX) (Moleculin or the Company), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting highly resistant tumors and viruses, today announced that Walter V. Klemp, Founder, President, CEO and Chairman, will participate in the Virtual Investor 2022 Top Picks Conference on Thursday, January 27, 2022 at 9:00 AM ET. |
MBRX Price Returns
| 1-mo | -5.63% |
| 3-mo | 7.09% |
| 6-mo | -27.05% |
| 1-year | -59.19% |
| 3-year | -77.12% |
| 5-year | -69.31% |
| YTD | -18.82% |
| 2021 | -61.11% |
| 2020 | -12.89% |
| 2019 | -12.01% |
| 2018 | -44.09% |
| 2017 | -18.42% |
Loading social stream, please wait...